What’s Next for Achillion Pharmaceuticals, Inc. (ACHN) After Today’s Big Increase?

April 17, 2018 - By Michael Collier

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Logo

Investors sentiment increased to 2.08 in 2017 Q4. Its up 1.12, from 0.96 in 2017Q3. It increased, as 10 investors sold Achillion Pharmaceuticals, Inc. shares while 28 reduced holdings. 34 funds opened positions while 45 raised stakes. 110.36 million shares or 4.96% more from 105.14 million shares in 2017Q3 were reported.
Jpmorgan Chase And has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 1.16 million shares. Financial Architects reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). State Of Wisconsin Investment Board holds 85,000 shares. 1832 Asset Mgmt Limited Partnership reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Clarivest Asset Management accumulated 0.01% or 141,671 shares. Illinois-based Grp One Trading Lp has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Moreover, Legal & General Group Pcl has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 46,345 shares. Integral Derivatives Ltd Company reported 15,368 shares. 401,200 were accumulated by Stifel Financial. California State Teachers Retirement Sys invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Sarissa Cap Mngmt Ltd Partnership invested in 2.50M shares or 1.84% of the stock. 2.86M were accumulated by Baker Bros Advsr L P. Hightower Advsrs Lc reported 13,300 shares. Moreover, Deutsche National Bank & Trust Ag has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Cornerstone Cap Ltd Liability Co reported 97,088 shares or 0% of all its holdings.

The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! The stock increased 7.87% or $0.28 during the last trading session, reaching $3.84. About 1.32 million shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since April 17, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.
The move comes after 5 months positive chart setup for the $529.51 million company. It was reported on Apr, 17 by Barchart.com. We have $3.96 PT which if reached, will make NASDAQ:ACHN worth $15.89M more.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on May, 3. They expect $-0.14 earnings per share, up 6.67 % or $0.01 from last year’s $-0.15 per share. After $-0.17 actual earnings per share reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -17.65 % EPS growth.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 4 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Achillion Pharmaceuticals had 5 analyst reports since October 23, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 11 by Leerink Swann. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by FBR Capital on Friday, February 23. Robert W. Baird maintained the shares of ACHN in report on Monday, October 23 with “Hold” rating. The rating was initiated by FBR Capital on Wednesday, February 7 with “Hold”.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $529.51 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.